On September 7, MEDCAPTAIN fell 34.57% in regular trading, trading at HK$10.1 per share, with turnover of HK$100 million. The stock officially debuted on the Hong Kong Stock Exchange main board, opening at HK$10.00 per share, approximately 35% below the IPO offer price of HK$15.42.
On the news front, the steep first-day decline followed earlier warning signs during the grey market session, where shares had already fallen over 17%. Despite the Hong Kong public offering being oversubscribed approximately 436.37 times with 57,305 valid applications, the stock failed to hold its offer price. The international tranche was moderately oversubscribed at 2.35 times. At a lot size of 100 shares, subscribers who received an allocation faced a paper loss of approximately HK$542 per lot. The company raised net proceeds of approximately HK$496 million from the IPO. Market participants noted that the absence of cornerstone investors, combined with the company reporting a net loss of RMB 2.5 million in Q1 due to share-based payments and listing expenses, may have contributed to pricing pressure.
MEDCAPTAIN is a China-based global medical device provider operating through three segments: Life Support Products, Minimally Invasive Interventional Products, and In Vitro Diagnostic Medical Devices, with products sold across more than 140 countries and regions.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments